AU2022326573A1 - Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer - Google Patents

Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer Download PDF

Info

Publication number
AU2022326573A1
AU2022326573A1 AU2022326573A AU2022326573A AU2022326573A1 AU 2022326573 A1 AU2022326573 A1 AU 2022326573A1 AU 2022326573 A AU2022326573 A AU 2022326573A AU 2022326573 A AU2022326573 A AU 2022326573A AU 2022326573 A1 AU2022326573 A1 AU 2022326573A1
Authority
AU
Australia
Prior art keywords
pyridin
alkyl
trifluoromethyl
group
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022326573A
Other languages
English (en)
Inventor
Martin Andersson
Madhumita BOGDAN
Daniel L. Flynn
Yasmin YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of AU2022326573A1 publication Critical patent/AU2022326573A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022326573A 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer Pending AU2022326573A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232983P 2021-08-13 2021-08-13
US63/232,983 2021-08-13
US202263317500P 2022-03-07 2022-03-07
US63/317,500 2022-03-07
PCT/US2022/074925 WO2023019259A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2022326573A1 true AU2022326573A1 (en) 2024-02-15

Family

ID=83188606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022326573A Pending AU2022326573A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Country Status (7)

Country Link
US (1) US20250127790A1 (https=)
EP (1) EP4384180A1 (https=)
JP (1) JP2024532780A (https=)
AU (1) AU2022326573A1 (https=)
CA (1) CA3228766A1 (https=)
TW (1) TW202320797A (https=)
WO (1) WO2023019259A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
WO2019038387A1 (en) * 2017-08-23 2019-02-28 Sprint Bioscience Ab PYRIDYLPYRIDONE COMPOUNDS
CN111094271B (zh) * 2017-08-23 2023-02-28 思普瑞特生物科学公司 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Also Published As

Publication number Publication date
JP2024532780A (ja) 2024-09-10
TW202320797A (zh) 2023-06-01
WO2023019259A1 (en) 2023-02-16
CA3228766A1 (en) 2023-02-16
EP4384180A1 (en) 2024-06-19
US20250127790A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
CN114072397B (zh) 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
KR102923990B1 (ko) Fgfr 저해제 및 이의 사용 방법
JP7626722B2 (ja) アミノピリミジンアミドオートファジー阻害剤およびその使用方法
TWI694076B (zh) 三唑并嘧啶化合物及其用途
US20240376058A1 (en) Gcn2 and perk kinase inhibitors and methods of use thereof
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
RS65019B1 (sr) Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
TW202108572A (zh) Ｃｄｋ抑制劑
TW201819386A (zh) Shp2磷酸酶抑制劑及其使用方法
JP2013522292A (ja) インダゾール化合物およびそれらの使用
JP2016014037A (ja) 縮合複素環式化合物およびそれらの使用
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
EP3479843A1 (en) Use of nox inhibitors for treatment of cancer
TW202341982A (zh) Ｃｄｋ２抑制劑及其用途
KR102651420B1 (ko) 치료 헤테로시클릭 화합물
US20250127790A1 (en) Combination therapy using vps34 inhibitors
US12577249B2 (en) GCN2 and perk kinase inhibitors and methods of use thereof
US20260041669A1 (en) Solid forms of a cdk inhibitor
CN118201619A (zh) Vps34抑制剂与sting激动剂的组合疗法用于治疗癌症
CN118715223A (zh) 作为gcn2和perk激酶抑制剂的杂环化合物
EA052732B1 (ru) Гетероциклические соединения в качестве ингибиторов киназ gcn2 и perk
HK40062784A (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
KR20220132538A (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
TW202542128A (zh) Ｖｐｓ３４抑制劑及其使用方法